Members Capital Advisors Inc. Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Members Capital Advisors Inc. decreased its position in Pfizer Inc. (NYSE:PFE) by 85.9% during the 4th quarter, Holdings Channel reports. The firm owned 4,005 shares of the biopharmaceutical company’s stock after selling 24,450 shares during the period. Pfizer comprises about 0.3% of Members Capital Advisors Inc.’s holdings, making the stock its 26th biggest holding. Members Capital Advisors Inc.’s holdings in Pfizer were worth $115,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Tokio Marine Asset Management Co. Ltd. grew its holdings in shares of Pfizer by 4.7% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,407 shares of the biopharmaceutical company’s stock worth $3,726,000 after purchasing an additional 5,859 shares during the last quarter. Capital Advisors Ltd. LLC boosted its holdings in Pfizer by 7.1% in the fourth quarter. Capital Advisors Ltd. LLC now owns 14,836 shares of the biopharmaceutical company’s stock valued at $427,000 after acquiring an additional 978 shares in the last quarter. Cognios Beta Neutral Large Cap Fund LP boosted its holdings in Pfizer by 4.3% in the fourth quarter. Cognios Beta Neutral Large Cap Fund LP now owns 18,066 shares of the biopharmaceutical company’s stock valued at $520,000 after acquiring an additional 739 shares in the last quarter. Wynn Capital LLC bought a new stake in Pfizer in the fourth quarter valued at $617,000. Finally, Mizuho Securities Co. Ltd. boosted its holdings in Pfizer by 261.7% in the fourth quarter. Mizuho Securities Co. Ltd. now owns 3,700 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 2,677 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Performance

NYSE:PFE traded down $0.06 during mid-day trading on Wednesday, reaching $26.26. The company’s stock had a trading volume of 24,501,011 shares, compared to its average volume of 41,887,898. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37. The firm’s fifty day moving average price is $27.05 and its two-hundred day moving average price is $28.50. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market cap of $148.70 billion, a P/E ratio of 72.94, a PEG ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.14 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.40%. Pfizer’s dividend payout ratio is currently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.